中國心髒支架産業發展報告

增速之所以放緩主要歸于三個(gè)緣由：一是高(gāo)值耗材招标帶來(lái)了降價風潮;二是由于患者多(duō)湧向三級醫(yī)院，因此三級醫(yī)院手術(shù)量基本飽和(hé)，目前基本處于平衡小(xiǎo)幅增長的階段;三則是廣大(dà)縣級地區(qū)受限于當地的醫(yī)療資源限制(zhì)和(hé)新農合報銷比例，增長緩慢。

2015

08-27

Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.

This study sought to perform a systematic review and network meta-analysis to compare the relative safety and efficacy of contemporary DES and BVS.

2015

08-04

Outcomes with bioabsorbable vascular scaffolds versus everolimus-eluting stents Insights from randomized trials

Bioresorbable vascular scaffolds (BVS) have been shown to be non-inferior to second generation drug eluting stents in recent clinical trials. However, the trials were not powered for individual endpoints and there is concern for increased device thrombosis with BVS.

2015

08-04

Everolimus-eluting bioresorbable vascular scaff olds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled

Bioresorbable coronary stents might improve outcomes of patients treated with percutaneous coronary interventions. The everolimus-eluting bioresorbable vascular scaffold is the most studied of these stent platforms; however, its performance versus everolimus-eluting metallic stents remains poorly defined. We aimed to assess the efficacy and safety of everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ischaemic heart disease treated with percutaneous revascularisation.

2015

08-04

A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimuseluting metallic stents in patients with coronary artery disease: ABSORB Japan

superior long-term results compared with permanent metallic drug-eluting stents (DESs). However, whether BVSs are as safe and effective as metallic DESs prior to complete bioresorption is unknown.

2015

08-03

首屆中國創新成果交流會(huì)在廣州舉辦

第一屆中國創新科技(jì)成果交流會(huì)5月22-23日在廣州白雲國際會(huì)議中心舉行(xíng)。我公司由北京生(shēng)物醫(yī)學工程學會(huì)推薦參加了此次創新成果交易會(huì)，本屆科交會(huì)共收集到1300多(duō)項科研成果進行(xíng)集中展示推介，經過前期對接，目前已有(yǒu)20項科研成果達成初步落地意向，有(yǒu)望在廣州得(de)到轉化，涉及投資金額約20億元。

2015

05-26

3D打印：還(hái)會(huì)給你(nǐ)更多(duō)驚喜

近日，公司董事長劉青博士接受《人(rén)民日報》采訪，對阿邁特研發的3D支架産品進行(xíng)了介紹，并對3D打印技(jì)術(shù)的現狀及未來(lái)發展前景發表了自己的見解，原文如下：

2014

09-02

2014世界3D打印技(jì)術(shù)産業大(dà)會(huì)圓滿落幕

3D打印技(jì)術(shù)作(zuò)為(wèi)一項前沿性、先導性很(hěn)強的技(jì)術(shù)，正在快速走進我們的生(shēng)活，引起各級政府組織、企業和(hé)社會(huì)各界的廣泛關注。

2014

06-24

國家(jiā)科技(jì)支撐計(jì)劃中期考評組來(lái)公司視(shì)察

2014年1月，由項目評審專家(jiā)奚廷斐教授、北航生(shēng)物與醫(yī)學工程學院院長樊瑜波教授組成的國家(jiā)科技(jì)支撐計(jì)劃中期考評組一行(xíng)4人(rén)，來(lái)我公司進行(xíng)了視(shì)察。

2014

04-30

3D打印可(kě)滿足個(gè)性化産品需求

騰訊科技(jì)訊2013年 5月31日消息，首屆世界3D打印技(jì)術(shù)産業産業大(dà)會(huì)于5月29-31日在北京中國大(dà)飯店(diàn)隆重舉行(xíng)。在會(huì)上(shàng)董事長劉青發表演講，劉青表示，3D打印能夠很(hěn)精确的控制(zhì)支架孔隙的大(dà)小(xiǎo)，可(kě)以做(zuò)細胞培養支架和(hé)可(kě)植入的産品，這是目前3D打印的優勢所在。

2014

04-30

< 1...11121314 > 前往 頁

公司信息

北京飛渡醫療器械有限公司

Beijing Advanced Medical Technologies,Ltd.Inc.

 

聯系我們

地址：北京市大(dà)興區(qū)永旺西路26号院中關村醫(yī)療器(qì)械園11号樓

電(diàn)話(huà)：010-6297-7955             郵箱：amt@ametcorp.com

圖片名稱

微信聯系

@Copyright 2022 北京飛渡醫療器械有限公司 All rights reserved   版權所有(yǒu)

京ICP備11028039号    網站(zhàn)建設：中企動力  南京